131 related articles for article (PubMed ID: 38069472)
1. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF; Schreiber S; D'Haens G; Rizzo J; Kligys K; Griffith J; Zambrano J; Zhou Q; Zhang Y; Kalabic J; Rieder F; Dubinsky MC; Panaccione R
J Crohns Colitis; 2024 Jun; 18(6):818-827. PubMed ID: 38069472
[TBL] [Abstract][Full Text] [Related]
2. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
3. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
[TBL] [Abstract][Full Text] [Related]
4. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
5. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M
Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154
[TBL] [Abstract][Full Text] [Related]
6. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
7. Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
Ferrante M; Irving PM; Abreu MT; Axler J; Gao X; Cao Q; Fujii T; Rausch A; Torres J; Neimark E; Song A; Wallace K; Kligys K; Berg S; Liao X; Zhou Q; Kalabic J; Feagan B; Panaccione R
J Crohns Colitis; 2024 Mar; 18(3):416-423. PubMed ID: 37797293
[TBL] [Abstract][Full Text] [Related]
8. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.
Kristensen LE; Soliman AM; Papp K; Barcomb L; Eldred A; Östör A
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2120-2129. PubMed ID: 35920763
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies.
Gao X; Fujii T; Ye BD; Chou JW; Sugimoto K; Cao Q; Kligys K; Murakoshi K; Teng D; Zhang Y; Nakase H
J Gastroenterol Hepatol; 2024 Jan; 39(1):55-65. PubMed ID: 37788676
[TBL] [Abstract][Full Text] [Related]
10. End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.
Wong ECL; Buffone E; Lee SJ; Dulai PS; Marshall JK; Reinisch W; Narula N
J Crohns Colitis; 2021 Jul; 15(7):1114-1119. PubMed ID: 33245751
[TBL] [Abstract][Full Text] [Related]
11. Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Peyrin-Biroulet L; Ghosh S; Lee SD; Lee WJ; Griffith J; Wallace K; Berg S; Liao X; Panes J; Loftus EV; Louis E
Aliment Pharmacol Ther; 2023 Mar; 57(5):496-508. PubMed ID: 36266762
[TBL] [Abstract][Full Text] [Related]
12. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
13. Risankizumab Concentration but not IL-22 Levels are Associated With Clinical and Biochemical Remission in Patients With Crohn's Disease.
Roblin X; Moschetti E; Barrau M; Cheifetz AS; Papamichael K; Paul S
Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38705437
[TBL] [Abstract][Full Text] [Related]
14. Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Feagan B; Sandborn WJ; Rutgeerts P; Levesque BG; Khanna R; Huang B; Zhou Q; Maa JF; Wallace K; Lacerda A; Thakkar RB; Robinson AM
Inflamm Bowel Dis; 2018 Apr; 24(5):932-942. PubMed ID: 29668919
[TBL] [Abstract][Full Text] [Related]
15. Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis.
Pray C; Wong ECL; Aruljothy A; Dulai PS; Marshall JK; Reinisch W; Narula N
Inflamm Bowel Dis; 2023 Aug; 29(8):1263-1271. PubMed ID: 36179118
[TBL] [Abstract][Full Text] [Related]
16. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
Sandborn WJ; Rutgeerts P; Colombel JF; Ghosh S; Petryka R; Sands BE; Mitra P; Luo A
J Crohns Colitis; 2017 Jul; 11(7):811-819. PubMed ID: 28333187
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Sands BE; Peyrin-Biroulet L; Kierkus J; Higgins PDR; Fischer M; Jairath V; Hirai F; D'Haens G; Belin RM; Miller D; Gomez-Valderas E; Naegeli AN; Tuttle JL; Pollack PF; Sandborn WJ
Gastroenterology; 2022 Feb; 162(2):495-508. PubMed ID: 34748774
[TBL] [Abstract][Full Text] [Related]
18. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2.
Ostor AJK; Soliman AM; Papp KA; Padilla B; Wang Z; Eldred A; de Vlam K; Kivitz A
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35701011
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Sandborn WJ; Dornic Q; Lindner D; Kisfalvi K; Marins EG; Vermeire S
Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):404-415. PubMed ID: 38417060
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
